SCHEMBL6033159

SCHEMBL6033159

CCOC(=O)c1ccc([Se]c2cc3c(cc2O)C(C)(C)CCC3(C)C)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 7/20 0.50
RARB P10826 7/20 0.50
CYP3A4 P08684 5/20 0.50
RARG P13631 4/20 0.50
KMT2A Q03164 2/20 0.50
RXRA P19793 7/20 0.41
RXRB P28702 4/20 0.41
RXRG P48443 4/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CYP26A1 O43174 3/20 0.40
CYP26B1 Q9NR63 1/20 0.40
HNF4A P41235 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033264 0.90 RARA (0.48) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032605 0.86 RXRA (0.48) RARARARBCYP3A4RARGKMT2A
SCHEMBL4956919 0.84 RXRA (0.51) RARARARBCYP3A4RARGRXRA
SCHEMBL6033270 0.83 RARA (0.43) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032722 0.83 RARB (0.47) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032626 0.83 RARG (0.49) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032646 0.83 RARA (0.43) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032621 0.81 RARA (0.42) RARARARBCYP3A4RARGKMT2A
SCHEMBL6032618 0.80 RARA (0.41) RARARARBCYP3A4RARGKMT2A
SCHEMBL6033253 0.80 RARA (0.41) RARARARBCYP3A4RARGKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US claimed
EP-1086080-B1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2004-08-25 EP claimed
US-6992094-B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US disclosed
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics TYR, DERL1, GPX1 RARA 2083/4885RARB 2125/4885CYP3A4 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.